Cancer Hospital of Guangxi Medical University

7 clinical trials · Sponsor

Record	Firm	Date
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma (NCT05707819)	Cancer Hospital of Guangxi Medical University	2022-07-30
Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma (NCT05131698)	Cancer Hospital of Guangxi Medical University	2021-03-01
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial (NCT04992988)	Cancer Hospital of Guangxi Medical University	2020-06-28
Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma (NCT04376866)	Cancer Hospital of Guangxi Medical University	2020-06-28
A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection (NCT03914352)	Cancer Hospital of Guangxi Medical University	2019-04-01
Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma (NCT02016417)	Cancer Hospital of Guangxi Medical University	2014-05-01
The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma (NCT02116231)	Cancer Hospital of Guangxi Medical University	2014-04-01

Every clearance here is in the API, with alerts when new ones post.